Skip to content

Study · Animal study (in vivo) · rat · 2006

3 results

Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus.

Rigamonti AE, Giordani C, Bonomo SM, Cella SG, Müller EE

European journal of pharmacology26 May 2006Cited by 18 (Europe PMC)

PMID16806163 (opens in a new tab)DOI10.1016/j.ejphar.2006.05.028 (opens in a new tab)PepBankPUB-16806163
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, hexarelin markedly stimulated feeding.

    In plain wordsIn rats, hexarelin strongly increased eating.

    Peptide
    Hexarelin
    Outcome
    IncreaseFood intake after hexarelin
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    160 microg/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    hexarelin (160 microg/kg s.c.) markedly stimulated feeding
    1 context sentence
    Summary · context
    This study investigated whether in rats, made tolerant to the hypophagic effect of SR141716, the drug was still capable to block the orexigenic activity of another non-natural (hypothalamic) peptide, i.e., the growth hormone releasing peptide (GHRP) hexarelin, a ghrelin mimetic.

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 02AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome

    In rats, each tested dose of the CB1 antagonist SR141716 reduced the orexigenic effect of the growth hormone releasing peptide hexarelin.

    In plain wordsIn rats, the drug SR141716 reduced the extra eating that hexarelin caused. The result is about SR141716, not hexarelin.

    Peptide
    Hexarelin
    Outcome
    DecreaseHexarelin-stimulated feeding in acute SR141716 experiment
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    All doses of SR141716 were capable to reduce the orexigenic effect of the GHRP.
    1 context sentence
    Summary · context
    This study investigated whether in rats, made tolerant to the hypophagic effect of SR141716, the drug was still capable to block the orexigenic activity of another non-natural (hypothalamic) peptide, i.e., the growth hormone releasing peptide (GHRP) hexarelin, a ghrelin mimetic.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 03AnimalNot a test of Hexarelin aloneAnimal study (in vivo)Efficacy outcome

    In rats that became tolerant to its hypophagic effect, SR141716 still suppressed the orexigenic effect of repeated hexarelin challenge tests.

    In plain wordsIn rats, the drug SR141716 kept blocking the extra eating hexarelin caused, even after tolerance to its own appetite effect. The result concerns SR141716.

    Peptide
    Hexarelin
    Outcome
    DecreaseHexarelin-stimulated feeding after chronic SR141716
    Study

    ratn: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Interestingly, despite development of tolerance to its hypophagic effect, SR141716 was capable to suppress the orexigenic effect of repeated hexarelin challenge tests performed throughout the chronic experiments.
    1 context sentence
    Summary · context
    This study investigated whether in rats, made tolerant to the hypophagic effect of SR141716, the drug was still capable to block the orexigenic activity of another non-natural (hypothalamic) peptide, i.e., the growth hormone releasing peptide (GHRP) hexarelin, a ghrelin mimetic.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.